At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 247 enrolled
Drug / intervention
LY3039478 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
In Brief
A Phase 1 clinical trial evaluating LY3039478 and Prednisone for Neoplasms and 2 related conditions. Completed, enrolled 247 participants across 11 sites in 6 countries.
Detailed Summary
The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells and tissue. Finally, the study will help to document any tumor activity this drug may have.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Neoplasm Metastasis, Lymphoma
CountriesDenmark, France, Germany, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartOct 2012
Primary CompletionJun 2018
TodayJul 2026
First PostedSep 27, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 26, 2018
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 13.8 years ago
Interventions
LY3039478drug
Administered orally
Prednisonedrug
Administered orally